Serum level changes of long chain-polyunsaturated fatty acids in patients undergoing periodontal therapy combined with one year of omega-3 supplementation: a pilot randomized clinical trial
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: We aimed to investigate the impact of nonsurgical periodontal treatment combined with one-year dietary supplementation with omega (ω)-3 on the serum levels of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and arachidonic acid (AA). Methods: Fifteen patients with chronic generalized periodontitis were treated with scaling and root planing. The test group consisted of seven patients (43.1±6.0 years) supplemented with ω-3, consisting of EPA plus DHA, three capsules, each of 300 mg of ω-3 (180-mg EPA/120-mg DHA), for 12 months. The control group was composed of eight patients (46.1±11.6 years) that took a placebo capsule for 12 months. The periodontal examination and the serum levels of DPA, EPA, DHA, and AA were performed at baseline (T0), and 4 (T1), and 12 (T2) months after therapy. Results: In the test group, AA and DPA levels had been reduced significantly at T1 (P<0.05). AA and EPA levels had been increased significantly at T2 (P<0.05). The ΔEPA was significantly higher in the test compared to the placebo group at T2–T0 (P=0.02). The AA/EPA had decreased significantly at T1 and T2 relative to baseline (P<0.05). Conclusions: Nonsurgical periodontal treatment combined with ω-3 supplementation significantly increased the EPA levels and decreased the AA/EPA ratio in serum after one year follow-up. However, no effect on the clinical outcome of periodontal therapy was observed.
Abstract
Purpose: We aimed to investigate the impact of nonsurgical periodontal treatment combined with one-year dietary supplementation with omega (ω)-3 on the serum levels of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and arachidonic acid (AA). Methods: Fifteen patients with chronic generalized periodontitis were treated with scaling and root planing. The test group consisted of seven patients (43.1±6.0 years) supplemented with ω-3, consisting of EPA plus DHA, three capsules, each of 300 mg of ω-3 (180-mg EPA/120-mg DHA), for 12 months. The control group was composed of eight patients (46.1±11.6 years) that took a placebo capsule for 12 months. The periodontal examination and the serum levels of DPA, EPA, DHA, and AA were performed at baseline (T0), and 4 (T1), and 12 (T2) months after therapy. Results: In the test group, AA and DPA levels had been reduced significantly at T1 (P<0.05). AA and EPA levels had been increased significantly at T2 (P<0.05). The ΔEPA was significantly higher in the test compared to the placebo group at T2–T0 (P=0.02). The AA/EPA had decreased significantly at T1 and T2 relative to baseline (P<0.05). Conclusions: Nonsurgical periodontal treatment combined with ω-3 supplementation significantly increased the EPA levels and decreased the AA/EPA ratio in serum after one year follow-up. However, no effect on the clinical outcome of periodontal therapy was observed.
참고문헌 (34)
- Seymour GJ, "Cytokines in periodontal disease: where to from here?", Acta Odontol Scand, 59, pp.167~173 (2001)
- Ott J, "Lipids in critical care medicine", Prostaglandins Leukot Essent Fatty Acids, 85, pp.267~273 (2011)
- Figueredo CM, "Serum levels of long-chain polyunsaturated fatty acids in patients with periodontal disease", J Periodontol, 84, pp.675~682 (2013)
- Martinez GL, "The impact of non-surgical periodontal treatment on serum levels of long chain-polyunsaturated fatty acids: a pilot randomized clinical trial", J Periodontal Res, 49, pp.268~274 (2014)
- Sijben JW, "Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease", Proc Nutr Soc, 66, pp.237~259 (2007)
- El-Sharkawy H, "Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin", J Periodontol, 81, pp.1635~1643 (2010)
- Elkhouli AM, "The efficacy of host response modulation therapy (omega-3 plus low-dose aspirin) as an adjunctive treatment of chronic periodontitis (clinical and biochemical study)", J Periodontal Res, 46, pp.261~268 (2011)
- Sonestedt E, "Do both heterocyclic amines and omega-6 polyunsaturated fatty acids contribute to the incidence of breast cancer in postmenopausal women of the Malmö diet and cancer cohort?", Int J Cancer, 123, pp.1637~1643 (2008)
- Khanaki K, "Evaluation of the relationship between endometriosis and omega-3 and omega-6 polyunsaturated fatty acids", Iran Biomed J, 16, pp.38~43 (2012)
- Simopoulos AP, "Omega-3 fatty acids in inflammation and autoimmune diseases", J Am Coll Nutr, 21, pp.495~505 (2002)
- Hayakawa S, "Association of plasma ω-3 to ω-6 polyunsaturated fatty acid ratio with complexity of coronary artery lesion", Intern Med, 51, pp.1009~1014 (2012)
- Naqvi AZ, "n-3 fatty acids and periodontitis in US adults", J Am Diet Assoc, 110, pp.1669~1675 (2010)
- "Fats and fatty acids in human nutrition. Proceedings of the Joint FAO", WHO Expert Consultation. November 10-14, 2008. Geneva, Switzerland, 2009, pp.55, 5~300
- Tong H, "Omega-3 fatty acid supplementation appears to attenuate particulate air pollution-induced cardiac effects and lipid changes in healthy middle-aged adults", Environ Health Perspect, 120, pp.952~957 (2012)
- Dawczynski C, "Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis", Br J Nutr, 101, pp.1517~1526 (2009)
- Gillies D, "Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents", Cochrane Database Syst Rev, 7, pp.CD007986~ (2012)
- Sydenham E, "Omega 3 fatty acid for the prevention of cognitive decline and dementia", Cochrane Database Syst Rev, 6, pp.CD005379~ (2012)
- Liu T, "Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials", Heart, 97, pp.1034~1040 (2011)
- James S, "Omega-3 fatty acids supplementation for autism spectrum disorders (ASD)", Cochrane Database Syst Rev, (11), pp.CD007992~ (2011)
- Friedman A, "Review of the effects of omega-3 supplementation in dialysis patients", Clin J Am Soc Nephrol, 1, pp.182~192 (2006)
- Armitage GC, "Development of a classification system for periodontal diseases and conditions", Ann Periodontol, 4, pp.1~6 (1999)
- WHO Expert Committee on Physical Status, "The use and interpretation of anthropometry" (1995), World Health Organization
- Rasmussen LE, "The content of docosahexaenoic acid in serum phospholipid is inversely correlated with plasma homocysteine levels in patients with end-stage renal disease", Nutr Res, 30, pp.535~540 (2010)
- Fredman G, "Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution", Biochem J, 437, pp.185~197 (2011)
- Gebauer SK, "n-3 fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits", Am J Clin Nutr, 83(6 Suppl), pp.1526S~1535S (2006)
- Simopoulos AP, "Omega-6", omega-3 essential fatty acids: biological effects, 2009, pp.99, 1~16
- Russo GL, "Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention", Biochem Pharmacol, 77, pp.937~946 (2009)
- Caramia G, "The essential fatty acids omega-6 and omega-3: from their discovery to their use in therapy", Minerva Pediatr, 60, pp.219~233 (2008)
- Gómez Candela C, "Importance of a balanced omega 6", omega 3 ratio for the maintenance of health: nutritional recommendations, 2011, pp.26, 323~329
- Rosenstein ED, "Pilot study of dietary fatty acid supplementation in the treatment of adult periodontitis", Prostaglandins Leukot Essent Fatty Acids, 68, pp.213~218 (2003)
- Hartweg J, "Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus", Cochrane Database Syst Rev, (1), pp.CD003205~ (2008)
- Akinkuolie AO, "Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials", Clin Nutr, 30, pp.702~707 (2011)
- Jacobson TA, "Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review", J Clin Lipidol, 6, pp.5~18 (2012)
- Ryan AS, "Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors", Am J Ther, 16, pp.183~192 (2009)